文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

BRAINSTORM:RRx-001联合全脑放疗治疗脑转移瘤的多中心1/2期研究

BRAINSTORM: A Multi-Institutional Phase 1/2 Study of RRx-001 in Combination With Whole Brain Radiation Therapy for Patients With Brain Metastases.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-03-10

这项多中心1/2期研究评估了血管正常化放射增敏剂RRx-001联合全脑放疗治疗脑转移瘤的推荐2期剂量及灌注MRI变化与疗效的相关性。2015至2017年共入组31例患者,未观察到剂量限制性毒性,最常见严重不良事件为3级乏力(6.9%)。颅内缓解率中位46%(95%CI 24-68),中位总生存5.2个月(95%CI 4.5-9.4),推荐2期剂量为10 mg每周两次。

要点

  • RRx-001联合全脑放疗耐受良好,未观察到剂量限制性毒性。
  • 中位颅内缓解率46%(95%CI 24-68),中位总生存5.2个月(95%CI 4.5-9.4)。
  • 推荐2期剂量为10 mg每周两次,24小时Vp下降与1和4个月肿瘤体积缩小相关(P≤.01)。

核心结论

  • RRx-001联合全脑放疗耐受良好且颅内缓解率良好,推荐2期剂量为10 mg每周两次。

研究设计与样本

  • 五中心参与的1/2期试验,RRx-001于全脑放疗前给药一次、放疗期间每周两次,计划四个剂量水平(5、8.4、16.5、27.5 mg/m2)。
  • 剂量爬坡采用时间-事件持续再评估法(TITE-CRM)算法管理,共入组31例患者,2例在治疗前退出。

主要发现

  • 最常见肿瘤类型为黑色素瘤(59%)和非小细胞肺癌(18%),中位年龄60岁(范围30-76),12例男性。
  • 未观察到剂量限制性毒性,最常见严重不良事件为3级乏力(6.9%,2/29)。
  • 中位颅内缓解率为46%(95%CI 24-68),中位总生存为5.2个月(95%CI 4.5-9.4),无神经性死亡。
  • 10例行动态对比增强MRI的患者中,RRx-001后24小时Vp下降与1和4个月肿瘤体积缩小相关(P≤.01)。

关键数值与推荐

  • 推荐2期剂量为10 mg每周两次,因各剂量水平均观察到活性。
  • 24小时T1、Ktrans(毛细血管通透性)和 fractional plasma volume 变化与肿瘤体积变化的相关性采用线性混合模型分析。

临床怎么用

  • RRx-001联合全脑放疗可作为脑转移瘤耐受良好的治疗选择,2期推荐剂量为10 mg每周两次。
  • 动态对比增强MRI示RRx-001后24小时Vp下降提示抗血管生成活性,或与较长疗程肿瘤缓解相关。

局限性

  • 样本量较小(31例入组,29例可评估),随访时间有限。
  • 仅10例患者行动态对比增强MRI,灌注影像与疗效相关性分析样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the recommended phase 2 dose of RRx-001, a radiosensitizer with vascular normalizing properties, when used with whole-brain radiation therapy (WBRT) for brain metastases and to assess whether quantitative changes in perfusion magnetic resonance imaging (MRI) after RRx-001 correlate with response. METHODS AND MATERIALS: Five centers participated in this phase 1/2 trial of RRx-001 given once pre-WBRT and then twice weekly during WBRT. Four dose levels were planned (5 mg/m2, 8.4 mg/m2, 16.5 mg/m2, 27.5 mg/m2). Dose escalation was managed by the time-to-event continual reassessment method algorithm. Linear mixed models were used to correlate change in 24-hour T1, Ktrans (capillary permeability), and fractional plasma volume with change in tumor volume. RESULTS: Between 2015 and 2017, 31 patients were enrolled. Two patients dropped out before any therapy. Median age was 60 years (range, 30-76), and 12 were male. The most common tumor types were melanoma (59%) and non-small cell lung cancer (18%). No dose limiting toxicities were observed. The most common severe adverse event was grade 3 asthenia (6.9%, 2 of 29). The median intracranial response rate was 46% (95% confidence interval, 24-68) and median overall survival was 5.2 months (95% confidence interval, 4.5-9.4). No neurologic deaths occurred. Among 10 patients undergoing dynamic contrast-enhanced MRI, a reduction in Vp 24 hours after RRx-001 was associated with reduced tumor volume at 1 and 4 months (P ≤ .01). CONCLUSIONS: The addition of RRx-001 to WBRT is well tolerated with favorable intracranial response rates. Because activity was observed across all dose levels, the recommended phase 2 dose is 10 mg twice weekly. A reduction in fractional plasma volume on dynamic contrast-enhanced MRI 24 hours after RRx-001 suggests antiangiogenic activity associated with longer-term tumor response.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Kim MM, Parmar HA, Schipper M, et al. BRAINSTORM: A Multi-Institutional Phase 1/2 Study of RRx-001 in Combination With Whole Brain Radiation Therapy for Patients With Brain Metastases. Int J Radiat Oncol Biol Phys. 2020. PMID: 32169409. doi:10.1016/j.ijrobp.2020.02.639

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。